Skip to main content

Table 8 Somatosensory evoked potentials in irradiated and non-irradiated groups

From: Clinical utility of complex assessment with evoked potentials in acute lymphoblastic leukemia survivors: comparison of various treatment protocols

 

NY + pBFM

BFM95

P value

Prolonged N9 latency

0 (0.0)

0 (0.0)

–

Decreased N9 amplitude

10 (12.2)

18 (21.7)

0.042

Prolonged N13 latency

4 (4.9)

0 (0.0)

0.339

Decreased N13 amplitude

7 (8.5)

4 (4.8)

0.339

Prolonged P14 latency

5 (6.1)

4 (4.8)

0.717

Prolonged N18 latency

20 (24.4)

0 (0.0)

< 0.001

Decreased N18 amplitude

31 (37.8)

22 (26.5)

0.120

Prolonged N20 latency

2 (2.4)

2 (2.4)

0.989

Decreased N20 amplitude

7 (8.5)

4 (4.8)

0.339

Prolonged P25 latency

0 (0.0)

0 (0.0)

–

Decreased P25 amplitude

7 (8.5)

4 (4.8)

0.339

Prolonged PCT

4 (4.9)

8 (9.6)

0.239

Prolonged CCT

5 (6.1)

7 (8.4)

0.563

N9 latency

9.20

8.75

0.002

N9 amplitude

5.74

6.98

0.007

N13 latency

12.15

11.73

0.018

N13 amplitude

2.32

3.16

0.038

P14 latency

13.74

13.39

0.100

P14 amplitude

2.01

1.73

0.429

N18 latency

16.83

16.50

0.139

N18 amplitude

2.78

3.70

0.009

N20 latency

18.29

17.75

0.012

N20 amplitude

1.74

1.72

0.924

P25 latency

21.42

21.22

0.460

P25 amplitude

3.71

3.90

0.639

PCT

2.95

2.97

0.857

CCT

6.14

6.03

0.564

  1. Abbreviations: BFM Berlin-Frankfurt-Münster protocol, CCT central conduction time, NY New York protocol, PCT peripheral conduction time